Status: Recruiting
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Participants needed: 24
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Rita AssiUpdated: Feb 10, 2026Locations: 2
Eligibility criteria
≥ 18 years old at the time of informed consent [+15]
Patients currently participating and receiving study therapy or has participated... [+24]